iCarbonX All

Since its establishment, iCarbonX All has always regarded technological innovation as its core driving force. Its self-developed silicon-based polypeptide chip technology breaks through traditional limitations and, combined with the high-throughput screening platform built using artificial intelligence, has become a unique and leading tool for large-scale efficient detection of protein interactions worldwide. This platform can precisely screen out the "optimal" drug candidate molecules from massive amounts of data, quickly completing the drug discovery phase, thus pressing the "acceleration button" for innovative drug research and development. Currently, the iCPDC-001 oncology project and the AI antimicrobial peptide project, both advanced through this platform, demonstrate Best-In-Class potential, with their pipeline strength continuing to lead the industry.